Polypill for cardiovascular disease prevention.

Polypill for cardiovascular disease prevention.

Détails bibliographiques
Auteur principal:	Dalton, A
Format:	Journal article
Langue:	English
Publié:	2013

Documents similaires

The Concept of the Polypill in the Prevention of Cardiovascular Disease
par: Brandon Wiley, et autres
Publié: (2014-04-01)

Polypills with or without aspirin for primary prevention of cardiovascular disease
par: Mant, J, et autres
Publié: (2021)

The feasibility of polypill for cardiovascular disease prevention in Asian Population
par: Apichard Sukonthasarn, et autres
Publié: (2021-03-01)

Use of cardiovascular polypills for the secondary prevention of cerebrovascular disease
par: J. Masjuan, et autres
Publié: (2021-01-01)

Medicinal herbs: Potential polypills in cardiovascular diseases
par: Samaneh Noroozi, et autres
Publié: (2021-04-01)

Polypills for Primary Prevention of Cardiovascular Disease: A Systematic Review and Meta-Analysis
par: Omneya A. Kandil, et autres
Publié: (2022-04-01)

The polypill: the solution for prevention of coronary heart disease?
par: Hendarto Natadidjaja
Publié: (2016-02-01)

THE ROLE OF POLYTABLETS (POLYPILL) IN THE TREATMENT OF CHRONIC CARDIOVASCULAR DISEASES
par: Николай Владимирович Абрамов, et autres
Publié: (2024-02-01)

Polypill versus medication monotherapy in the prevention of cardiovascular diseases in Iran: An economic evaluation study
par: Ramin Ravangard, et autres
Publié: (2024-07-01)

Practical Decision Algorithms for the Use of the Cardiovascular Polypill in Secondary Prevention in Europe
par: Lilian Grigorian-Shamagian, et autres
Publié: (2021-08-01)

The use of polypills in cardiovascular disease management: Benefits vs challenges
par: Yamaan Adil, et autres
Publié: (2024-09-01)

Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review
par: Lopez-Lopez JP, et autres
Publié: (2023-09-01)

A Polypill for primary prevention of cardiovascular disease: A feasibility study of the World Health Organization
par: Gunaratne Padma S, et autres
Publié: (2011-01-01)

A Survey of Availability and Affordability of Polypills for Cardiovascular Disease in Selected Countries
par: Gautam Satheesh, et autres
Publié: (2024-07-01)

Redefining the polypill: pros and cons in cardiovascular precision medicine
par: Siddharth Birla, et autres
Publié: (2023-09-01)

Exercise Rehabilitation in Heart Disease: the real “polypill” for primary and secondary prevention
par: Massimo F. Piepoli
Publié: (2005-06-01)

Correction: A Survey of Availability and Affordability of Polypills for Cardiovascular Disease in Selected Countries
par: Gautam Satheesh, et autres
Publié: (2024-08-01)

Preventing the progression of climate change: one drug or polypill?
par: Hugh Montgomery
Publié: (2017-03-01)

Polypill holds promise for people with chronic disease
par: Jacqui Wise
Publié: (2005-12-01)

Polypill" conception in modern cardiology
par: I E Chazova, et autres
Publié: (2018-12-01)

Polypill revisited – Unity in diversity
par: Gheorghe-Andrei Dan, et autres
Publié: (2020-08-01)

Cost-Effectiveness of the CNIC-Polypill Strategy Compared With Separate Monocomponents in Secondary Prevention of Cardiovascular and Cerebrovascular Disease in Portugal: The MERCURY Study
par: Carlos Aguiar, et autres
Publié: (2022-11-01)

Cost-effectiveness of fixed-dose combination pill (Polypill) in primary and secondary prevention of cardiovascular disease: A systematic literature review.
par: Reza Jahangiri, et autres
Publié: (2022-01-01)

Economic Burden Associated with the Treatment with a Cardiovascular Polypill in Secondary Prevention in Spain: Cost-Effectiveness Results of the NEPTUNO Study
par: Cordero A, et autres
Publié: (2023-07-01)

Three-dimensional printing of flexible polypill
par: Yasir Karkar, et autres
Publié: (2023-12-01)

Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease
par: Jowett, S, et autres
Publié: (2017)

Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease.
par: Sue Jowett, et autres
Publié: (2017-01-01)

Polypill Brings Benefits to Patients with Cardiovascular Disease, Both Improving Medication Adherence and Demonstrating the Concept of Chronotherapy [Letter]
par: Zhu LL, et autres
Publié: (2023-09-01)

The Benefits of Polypill: Adherence and Chronotherapy [Response to Letter]
par: Lopez-Jaramillo P, et autres
Publié: (2023-10-01)

Has the polypill finally proven its worth?
par: Treadwell, J
Publié: (2019)

Inclusion of Polypills for Prevention of Cardiovascular Disease in the 23rd World Health Organization Model List of Essential Medicines: A Significant Step Towards Reducing Global Cardiovascular Morbidity and Mortality
par: Anubha Agarwal, et autres
Publié: (2024-02-01)

The cardiovascular polypill as baseline treatment improves lipid profile and blood pressure regardless of body mass index in patients with cardiovascular disease. The Bacus study.
par: José Alejandro Chávez Fernández, et autres
Publié: (2023-01-01)

Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: a randomised controlled trial of a polypill-based strategy amongst Indigenous and non Indigenous people at high cardiovascular risk
par: Usherwood Tim, et autres
Publié: (2010-08-01)

Would primary healthcare professionals prescribe a polypill to manage cardiovascular risk? A qualitative interview study
par: Virdee, S, et autres
Publié: (2013)

Effect of a Cardiovascular Polypill on Poststroke Cognition Among Ghanaians: Secondary Analysis of a Randomized Clinical Trial
par: Fred Stephen Sarfo, et autres
Publié: (2024-08-01)

Randomized Polypill crossover trial in people aged 50 and over.
par: David S Wald, et autres
Publié: (2012-01-01)

Polypill therapy and frailty in elderly: Time to stop treating everything
par: Sunil Kumar, et autres
Publié: (2021-04-01)

The efficacy and tolerability of 'polypills': meta-analysis of randomised controlled trials.
par: C Raina Elley, et autres
Publié: (2012-01-01)

Randomized, multicenter, parallel, open, phase 4 study to compare the efficacy and safety of rosuvastatin/amlodipine polypill versus atorvastatin/amlodipine polypill in hypertension patient with dyslipidemia
par: Hae Won Jung, et autres
Publié: (2023-09-01)

An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk.
par: PILL Collaborative Group, et autres
Publié: (2011-01-01)